Simultaneous spatio-temporal measurement of gene expression and cellular activity
Provided herein are methods for simultaneous spatio-temporal measurement of gene expression and cellular activity.
1. A method for identifying location and/or abundance of an analyte in a plurality of live cells, the method comprising:
(a) contacting the plurality of live cells with a substrate comprising a plurality of capture probes, wherein a capture probe of the plurality of capture probes comprises (i) a spatial barcode and (ii) a capture domain that binds to a sequence present in the analyte;
(b) perfusing one or more test compounds through a perfusion chamber comprising a gasket and the substrate, wherein the gasket comprises (i) a plurality of apertures, (ii) a plurality of input channels connected to the plurality of apertures, and (iii) a plurality of output channels connected to the plurality of apertures, and wherein the plurality of live cells is located within the perfusion chamber;
(c) hybridizing the analyte to the capture domain of the capture probe;
(d) extending the capture probe using the analyte as a template, thereby generating an extended capture probe;
(e) amplifying the extended capture probe to produce a plurality of extended capture probes; and
(f) sequencing (i) the spatial barcode, or a complement thereof, and (ii) all or part of the sequence of the analyte, or a complement thereof, and using the determined sequences of (i) and (ii) to identify the location and/or abundance of the analyte in the plurality of live cells.
2. The method of claim 1 , further comprising recording a cellular activity or an intracellular gene expression of a nucleic acid in the plurality of live cells, wherein the recording occurs before steps (c), (d), (e), and (f).
3. The method of claim 1 , wherein the one or more test compounds comprise one or more drugs.
4. The method of claim 3 , wherein the one or more drugs comprise a small-molecule drug, an antibody or antigen-binding fragment thereof, a pharmacological agent, an anti-cancer drug, a chemotherapy, or an anti-viral drug.
5. The method of claim 1 , wherein the one or more test compounds comprise polypeptides, polynucleotides, inorganic or organic compounds, natural products, or members of a combinatorial chemistry library.
6. The method of claim 1 , wherein the one or more test compounds are conjugated with a fluorophore or an oligonucleotide.
7. The method of claim 1 , wherein each test compound of the one or more test compounds is conjugated with a barcode that uniquely identifies the test compound.
8. The method of claim 2 , wherein the one or more test compounds, after being perfused through the perfusion chamber, alter the cellular activity or the intracellular gene expression of the nucleic acid in the plurality of live cells.
9. The method of claim 2 , wherein the one or more test compounds induce a cellular activity or intracellular gene expression change, wherein the cellular activity change or intracellular gene expression change is recorded immediately following the perfusing step.
10. The method of claim 2 , wherein the perfusing step and the recording step are automatically performed for high-throughput screening of the one or more test compounds.
11. The method of claim 1 , further comprising perfusing a culture medium to remove the one or more test compounds from the perfusion chamber, followed by perfusing the same or different one or more test compounds in the perfusion chamber.
12. The method of claim 1 , wherein the one or more test compounds (i) are pre-mixed and (ii) perfused through the perfusion chamber at the same time.
13. The method of claim 1 , wherein the one or more test compounds are sequentially perfused through the perfusion chamber.
14. The method of claim 1 , wherein the one or more test compounds are repeatedly perfused through the perfusion chamber to induce a cellular activity or gene expression change.
15. The method of claim 2 , wherein results of the recording step can be combined with the location and/or abundance of the analyte in the plurality of live cells, to determine effects of the one or more compounds to the plurality of live cells.
16. The method of claim 2 , wherein the cellular activity comprises a kinase activity, phosphorylation activity, G protein-coupled receptor related activity, ion channel activity, ligand-receptor binding activity, neural activity, protein synthesis activity, protein expression and localization, transient optical activity, cell-to-cell interaction, cellular morphology, vesicular trafficking, protein translocation and/or protein post-translational modifications.
17. The method of claim 2 , wherein the cellular activity is associated with processes in a cell signaling pathway or cascade.
18. The method of claim 2 , wherein the cellular activity is associated with a conformational change of a protein or the nucleic acid.
19. The method of claim 2 , wherein the cellular activity occurs upon contacting one or more cells with a pharmacological compound.
20. The method of claim 2 , wherein the perfusing step occurs prior to the recording step, or wherein the perfusing step and the recording step occur at substantially the same time.
21. The method of claim 2 , further comprising culturing the plurality of live cells in the perfusion chamber before the recording step.
22. The method of claim 2 , wherein the recording step comprises optical recording.
23. The method of claim 1 , wherein the plurality of live cells is cultured in a culture medium in the perfusion chamber.
24. The method of claim 1 , wherein the plurality of live cells is a cell culture sample or a tissue sample.
25. The method of claim 1 , wherein the plurality of live cells is stained by immunohistochemistry or immunofluorescence before the recording step.
26. The method of claim 1 , wherein the plurality of live cells is imaged using bright field imaging.
27. The method of claim 1 , wherein the extending step comprises extending the capture probe at its 3′ end.
28. The method of claim 1 , wherein the plurality of live cells is removed after the amplifying step.
29. The method of claim 1 , wherein the amplifying step comprises amplifying (i) all or part of the sequence of the analyte hybridized to the capture domain, or a complement thereof, and (ii) the spatial barcode, or a complement thereof.
30. The method of claim 2 , wherein the identifying further comprises correlating the recording of the intracellular gene expression of the nucleic acid in the plurality of live cells to the location and/or abundance of the analyte in the plurality of live cells.